Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 14/20 | 0.48 |
| ▸ | RXRG | P48443 | 9/20 | 0.48 |
| ▸ | RXRB | P28702 | 8/20 | 0.48 |
| ▸ | RARB | P10826 | 5/20 | 0.48 |
| ▸ | RARG | P13631 | 4/20 | 0.48 |
| ▸ | RARA | P10276 | 3/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | CYP26B1 | Q9NR63 | 8/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 7/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8332791 | 1.00 | RXRA (0.48) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL8332983 | 1.00 | RXRA (0.48) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL21017967 | 1.00 | RXRA (0.48) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL8475418 | 0.82 | RARA (0.42) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL8672117 | 0.82 | RARB (0.43) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL8667594 | 0.82 | RARA (0.40) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL21017939 | 0.80 | RXRA (0.39) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL8340501 | 0.80 | RXRA (0.52) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL6756499 | 0.78 | PTGS1 (0.45) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL6757746 | 0.78 | PTGS1 (0.45) | RXRARXRGRXRBRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115010577-A | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | IO治疗公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-111465402-B | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | IO治疗公司 | 2022-05-24 | — | — | CN | disclosed |
| US-20210139404-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | Io Therapeutics, Inc. | 2021-05-13 | — | — | US | disclosed |
| US-20210139404-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | Io Therapeutics, Inc. | 2021-05-13 | — | — | US | disclosed |
| US-10919835-B2 | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | Io Therapeutics, Inc. (US) | 2021-02-16 | — | — | US | disclosed |
| US-10919835-B2 | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | Io Therapeutics, Inc. (US) | 2021-02-16 | — | — | US | disclosed |
| EP-3710027-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | IO Therapeutics, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-111465402-A | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | IO治疗公司 | 2020-07-28 | — | — | CN | disclosed |
| US-20200190008-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-18 | — | — | US | disclosed |
| US-20200190008-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-18 | — | — | US | disclosed |
| US-10590059-B2 | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | Io Therapeutics, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10590059-B2 | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | Io Therapeutics, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190152888-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | Io Therapeutics, Inc. | 2019-05-23 | — | — | US | disclosed |
| US-20190152888-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | Io Therapeutics, Inc. | 2019-05-23 | — | — | US | disclosed |
| WO-1999008992-A1 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 1999-02-25 | — | — | WO | disclosed |
| EP-0848696-A1 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | Allergan (US) | 1998-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152888-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | RXRG, RXRB, RXRA | RXRA 3/4885RXRG 1/4885RXRB 2/4885 |
| US-20200190008-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | RXRG, RXRB, RXRA | RXRA 3/4885RXRG 1/4885RXRB 2/4885 |
| US-10590059-B2 | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | RXRG, RXRB, RXRA | RXRA 3/4885RXRG 1/4885RXRB 2/4885 |
| US-10919835-B2 | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | RXRG, RXRB, RXRA | RXRA 3/4885RXRG 1/4885RXRB 2/4885 |
| US-20210139404-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | RXRG, RXRB, RXRA | RXRA 3/4885RXRG 1/4885RXRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.